Source:http://linkedlifedata.com/resource/pubmed/id/16118081
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2005-8-24
|
| pubmed:abstractText |
This experience of single agent interferon-alpha treatment in high-grade osteosarcoma was based on observed anti-osteosarcoma activity in laboratory models and was started before introduction of aggressive combination chemotherapy. From 1971 to 1990, 89 consecutive patients with non-metastatic high-grade osteosarcoma received semi-purified, leukocyte interferon-alpha as adjuvant treatment. From 1971 to 1984, 70 patients were given a dose of 3 MIU daily for one month followed by 3 times weekly for an additional 17 months. For 19 patients treated from 1985 to 1990 the dose was increased to 3 MIU daily and the treatment duration extended to 3-5 years. All patients underwent surgery prior to interferon treatment. The toxicity was mainly constitutional and long-term toxicity was virtually absent. With a median follow-up of 12 years the observed 10-year metastases-free and sarcoma specific survival rates were 39% and 43%, respectively. Only one of seven survivors after relapse received chemotherapy. This work suggests activity of interferon-alpha as adjuvant treatment in high-grade osteosarcoma. The efficacy of interferon in combination with standard therapy should be explored in randomized trials.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0284-186X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
44
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
475-80
|
| pubmed:dateRevised |
2009-5-12
|
| pubmed:meshHeading |
pubmed-meshheading:16118081-Adolescent,
pubmed-meshheading:16118081-Adult,
pubmed-meshheading:16118081-Aged,
pubmed-meshheading:16118081-Antineoplastic Agents,
pubmed-meshheading:16118081-Bone Neoplasms,
pubmed-meshheading:16118081-Chemotherapy, Adjuvant,
pubmed-meshheading:16118081-Child,
pubmed-meshheading:16118081-Child, Preschool,
pubmed-meshheading:16118081-Extremities,
pubmed-meshheading:16118081-Female,
pubmed-meshheading:16118081-Follow-Up Studies,
pubmed-meshheading:16118081-Humans,
pubmed-meshheading:16118081-Interferon-alpha,
pubmed-meshheading:16118081-Lung Neoplasms,
pubmed-meshheading:16118081-Male,
pubmed-meshheading:16118081-Middle Aged,
pubmed-meshheading:16118081-Neoplasm Recurrence, Local,
pubmed-meshheading:16118081-Neoplasm Staging,
pubmed-meshheading:16118081-Osteosarcoma,
pubmed-meshheading:16118081-Survival Analysis,
pubmed-meshheading:16118081-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series.
|
| pubmed:affiliation |
Department of Tumour Biology, The Norwegian Radiumhospital, Oslo, Norway. christoph.muller@klinmed.uio.no
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|